You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 2020356356113
Nov 202010610649
Dec 2020717127
Jan 2021777735
Feb 2021434324
Mar 2021525230
Apr 2021353515
May 2021454544
Jun 2021434331
Jul 2021585834
Aug 2021454526
Sep 2021303020
Oct 2021525254
Nov 2021777744
Dec 2021464626
Jan 2022454724
Feb 2022393923
Mar 2022434329
Apr 2022414327
May 2022505029
Jun 2022495433
Jul 2022313318
Aug 2022444534
Sep 2022404133
Oct 2022525443
Nov 2022393925
Dec 2022333318
Jan 2023363613
Feb 2023586015
Mar 2023505124
Apr 2023191915
May 2023323214
Jun 202321219
Jul 2023202023
Aug 2023333316
Sep 2023323316
Oct 2023343414
Nov 2023363615
Dec 2023363615
Jan 2024303121
Feb 2024464720
Mar 2024505099
Total217521961237